CASSAVA SCIENCES INC. - COMMON STOCK

Cassava Reports Q2 2025 Financials Results and Provides Business Update

14 Aug 2025 04:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

07 Aug 2025 04:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

04 Aug 2025 04:30:00 By Nasdaq GlobeNewswire

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

30 Jun 2025 04:00:00 By Nasdaq GlobeNewswire

Cassava Reports Q1 2025 Financials Results, Provides Business Update

08 May 2025 05:00:01 By Nasdaq GlobeNewswire

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

01 May 2025 04:30:00 By Nasdaq GlobeNewswire

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

21 Apr 2025 13:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

25 Mar 2025 05:05:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

03 Mar 2025 04:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Licenses Simufilam Method of Treatment Patent

27 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Cassava Sciences Provides a Business Update

07 Jan 2025 13:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

25 Nov 2024 04:30:00 By Nasdaq GlobeNewswire

Cassava Sciences to Hold Corporate Update on November 25th

24 Nov 2024 17:01:09 By Nasdaq GlobeNewswire

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

18 Nov 2024 05:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports Q3 2024 Financial and Operating Results

07 Nov 2024 04:55:00 By Nasdaq GlobeNewswire

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

31 Oct 2024 05:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Resolves SEC Investigation

26 Sep 2024 15:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

24 Sep 2024 05:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Names Rick Barry as Chief Executive Officer

09 Sep 2024 05:30:00 By Nasdaq GlobeNewswire

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

03 Sep 2024 05:31:00 By Nasdaq GlobeNewswire